Cargando…
Outpatient prescription of pulmonary vasodilator therapy to preterm children with bronchopulmonary dysplasia
AIM: The use of pulmonary vasodilator therapy in children born preterm is largely unknown. Our aim was to map prescription patterns in children with bronchopulmonary dysplasia in Sweden. METHODS: This was a descriptive national registry‐based study of children <7 years who had been prescribed a p...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108203/ https://www.ncbi.nlm.nih.gov/pubmed/36478302 http://dx.doi.org/10.1111/apa.16615 |
_version_ | 1785026799819816960 |
---|---|
author | Jeremiasen, Ida Tran‐Lundmark, Karin Dolk, Mikaela Naumburg, Estelle |
author_facet | Jeremiasen, Ida Tran‐Lundmark, Karin Dolk, Mikaela Naumburg, Estelle |
author_sort | Jeremiasen, Ida |
collection | PubMed |
description | AIM: The use of pulmonary vasodilator therapy in children born preterm is largely unknown. Our aim was to map prescription patterns in children with bronchopulmonary dysplasia in Sweden. METHODS: This was a descriptive national registry‐based study of children <7 years who had been prescribed a pulmonary vasodilator during 2007–2017, were born preterm and classified as having bronchopulmonary dysplasia. Information on prescriptions, patient characteristics and comorbidities were retrieved from the Swedish Prescribed Drug Register and linked to other national registers. RESULTS: The study included 74 children, 54 (73%) born at 22–27 weeks' gestation and 20 (27%) at 28–36 weeks. Single therapy was most common, n = 64 (86.5%), and sildenafil was prescribed most frequently, n = 69 (93%). Bosentan, iloprost, macitentan and/or treprostinil were used mainly for combination therapies, n = 10 (13.5%). Patent ductus arteriosus or atrial septal defect were present in 29 (39%) and 25 (34%) children, respectively, and 20 (69%) versus 3 (12%) underwent closure. Cardiac catheterisation was performed in 19 (26%) patients. Median duration of therapy was 4.6 (1.9‐6.8, 95% CI) months. Mortality was 9%. CONCLUSION: Preterm children with bronchopulmonary dysplasia were prescribed pulmonary vasodilators, often without prior catheterisation. Sildenafil was most commonly used. Diagnostic tools, effects, and drug safety need further evaluation. |
format | Online Article Text |
id | pubmed-10108203 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101082032023-04-18 Outpatient prescription of pulmonary vasodilator therapy to preterm children with bronchopulmonary dysplasia Jeremiasen, Ida Tran‐Lundmark, Karin Dolk, Mikaela Naumburg, Estelle Acta Paediatr Original Articles & Brief Reports AIM: The use of pulmonary vasodilator therapy in children born preterm is largely unknown. Our aim was to map prescription patterns in children with bronchopulmonary dysplasia in Sweden. METHODS: This was a descriptive national registry‐based study of children <7 years who had been prescribed a pulmonary vasodilator during 2007–2017, were born preterm and classified as having bronchopulmonary dysplasia. Information on prescriptions, patient characteristics and comorbidities were retrieved from the Swedish Prescribed Drug Register and linked to other national registers. RESULTS: The study included 74 children, 54 (73%) born at 22–27 weeks' gestation and 20 (27%) at 28–36 weeks. Single therapy was most common, n = 64 (86.5%), and sildenafil was prescribed most frequently, n = 69 (93%). Bosentan, iloprost, macitentan and/or treprostinil were used mainly for combination therapies, n = 10 (13.5%). Patent ductus arteriosus or atrial septal defect were present in 29 (39%) and 25 (34%) children, respectively, and 20 (69%) versus 3 (12%) underwent closure. Cardiac catheterisation was performed in 19 (26%) patients. Median duration of therapy was 4.6 (1.9‐6.8, 95% CI) months. Mortality was 9%. CONCLUSION: Preterm children with bronchopulmonary dysplasia were prescribed pulmonary vasodilators, often without prior catheterisation. Sildenafil was most commonly used. Diagnostic tools, effects, and drug safety need further evaluation. John Wiley and Sons Inc. 2022-12-16 2023-03 /pmc/articles/PMC10108203/ /pubmed/36478302 http://dx.doi.org/10.1111/apa.16615 Text en © 2022 The Authors. Acta Paediatrica published by John Wiley & Sons Ltd on behalf of Foundation Acta Paediatrica. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles & Brief Reports Jeremiasen, Ida Tran‐Lundmark, Karin Dolk, Mikaela Naumburg, Estelle Outpatient prescription of pulmonary vasodilator therapy to preterm children with bronchopulmonary dysplasia |
title | Outpatient prescription of pulmonary vasodilator therapy to preterm children with bronchopulmonary dysplasia |
title_full | Outpatient prescription of pulmonary vasodilator therapy to preterm children with bronchopulmonary dysplasia |
title_fullStr | Outpatient prescription of pulmonary vasodilator therapy to preterm children with bronchopulmonary dysplasia |
title_full_unstemmed | Outpatient prescription of pulmonary vasodilator therapy to preterm children with bronchopulmonary dysplasia |
title_short | Outpatient prescription of pulmonary vasodilator therapy to preterm children with bronchopulmonary dysplasia |
title_sort | outpatient prescription of pulmonary vasodilator therapy to preterm children with bronchopulmonary dysplasia |
topic | Original Articles & Brief Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108203/ https://www.ncbi.nlm.nih.gov/pubmed/36478302 http://dx.doi.org/10.1111/apa.16615 |
work_keys_str_mv | AT jeremiasenida outpatientprescriptionofpulmonaryvasodilatortherapytopretermchildrenwithbronchopulmonarydysplasia AT tranlundmarkkarin outpatientprescriptionofpulmonaryvasodilatortherapytopretermchildrenwithbronchopulmonarydysplasia AT dolkmikaela outpatientprescriptionofpulmonaryvasodilatortherapytopretermchildrenwithbronchopulmonarydysplasia AT naumburgestelle outpatientprescriptionofpulmonaryvasodilatortherapytopretermchildrenwithbronchopulmonarydysplasia |